content/10.introduction.md:6:biomedicine
content/10.introduction.md:8:omics
content/10.introduction.md:11:covariates
content/10.introduction.md:12:Vemurafenib
content/10.introduction.md:13:omics
content/10.introduction.md:14:explainability
content/10.introduction.md:14:identifiability
content/16.background.md:5:priori
content/16.background.md:7:generalisable
content/16.background.md:10:biomedicine
content/16.background.md:14:directionality
content/16.background.md:15:ERK
content/16.background.md:15:ERK
content/16.background.md:15:MEK
content/16.background.md:15:MEK
content/16.background.md:16:directionality
content/16.background.md:17:ERK
content/16.background.md:17:phosphoproteomic
content/16.background.md:25:Orthogonally
content/16.background.md:26:counterfactuals
content/16.background.md:27:CRISPR
content/16.background.md:27:ERK
content/16.background.md:27:ERK
content/16.background.md:27:interventional
content/16.background.md:27:MEK
content/16.background.md:28:interventional
content/16.background.md:30:interventional
content/16.background.md:31:interventional
content/16.background.md:32:CRISPR
content/16.background.md:32:interventional
content/16.background.md:41:EGFR
content/16.background.md:41:ERK
content/16.background.md:41:MEK
content/16.background.md:41:RAS
content/16.background.md:41:Vemurafenib
content/16.background.md:41:Vemurafenib
content/16.background.md:44:Vemurafenib
content/16.background.md:46:MAPK
content/16.background.md:46:overactivation
content/16.background.md:46:Vemurafenib
content/16.background.md:47:EGFR
content/16.background.md:47:MEK
content/20.bias.md:11:overfitting
content/20.bias.md:11:underfitting
content/20.bias.md:26:biomedicine
content/30.prior_knowledge.md:30:SCMs
content/30.prior_knowledge.md:35:overfitting
content/30.prior_knowledge.md:36:CNNs
content/30.prior_knowledge.md:36:Convolutional
content/30.prior_knowledge.md:36:RNNs
content/30.prior_knowledge.md:40:interpretable
content/30.prior_knowledge.md:41:datasets
content/30.prior_knowledge.md:42:datasets
content/30.prior_knowledge.md:43:interpretability
content/30.prior_knowledge.md:43:overfitting
content/30.prior_knowledge.md:45:tradeoff
content/40.foundation_models.md:3:LLMs
content/40.foundation_models.md:4:LLMs
content/40.foundation_models.md:5:GPT
content/40.foundation_models.md:5:Pre
content/40.foundation_models.md:7:Geneformer
content/40.foundation_models.md:10:LLMs
content/40.foundation_models.md:12:generalisable
content/40.foundation_models.md:13:pre
content/40.foundation_models.md:15:scVI
content/40.foundation_models.md:18:corpuses
content/40.foundation_models.md:18:corpuses
content/40.foundation_models.md:18:Geneformer
content/40.foundation_models.md:18:LLMs
content/40.foundation_models.md:18:scGPT
content/40.foundation_models.md:19:LLMs
content/40.foundation_models.md:25:GPT
content/40.foundation_models.md:25:LLMs
content/40.foundation_models.md:26:generalisable
content/40.foundation_models.md:31:Explainability
content/40.foundation_models.md:31:linearities
content/40.foundation_models.md:34:interpretable
content/40.foundation_models.md:37:Geneformer
content/40.foundation_models.md:37:Theodoris
content/40.foundation_models.md:38:interpretable
content/40.foundation_models.md:40:Benchmarking
content/40.foundation_models.md:40:overfitting
content/40.foundation_models.md:41:overfitting
content/40.foundation_models.md:42:generalisable
content/40.foundation_models.md:44:GPT
content/40.foundation_models.md:44:LLM
content/40.foundation_models.md:52:dimensionality
content/40.foundation_models.md:52:PCA
content/40.foundation_models.md:52:SNE
content/40.foundation_models.md:52:UMAP
content/40.foundation_models.md:54:datasets
content/40.foundation_models.md:54:interpretable
content/40.foundation_models.md:72:embeddings
content/50.discussion.md:7:unfeasibly
content/50.discussion.md:9:scalability
content/50.discussion.md:21:interventional
content/50.discussion.md:23:interventional
content/50.discussion.md:26:biassed
content/50.discussion.md:27:Interventional
content/50.discussion.md:28:interpretability
content/50.discussion.md:28:interventional
content/50.discussion.md:32:generalisable
content/50.discussion.md:33:LLMs
content/50.discussion.md:40:facto
content/50.discussion.md:43:datasets
content/50.discussion.md:45:datasets
content/50.discussion.md:46:interventional
content/90.back-matter.md:3:Aurelien
content/90.back-matter.md:3:Dugourd
content/90.back-matter.md:7:PerMedCoE
content/90.back-matter.md:7:Programme
content/90.back-matter.md:11:Astex
content/90.back-matter.md:11:Grunenthal
content/90.back-matter.md:11:GSK
content/90.back-matter.md:11:honoraria
content/90.back-matter.md:11:JSR
content/90.back-matter.md:11:Sanofi
content/90.back-matter.md:11:Stadapharm
content/90.back-matter.md:11:Travere
content/XX.potential_references.md:1:LLMs
content/XX.potential_references.md:3:LLM
